

**Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study**

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- diagnosis of advanced melanoma or squamous cell head and neck cancer - cancer has worsened during or shortly after prior PD-1 immunotherapy treatment - able to care for yourself and perform most daily activities - must not be pregnant or breastfeeding - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete inclusion criteria

### Conditions & Interventions

**Conditions:**

Cancer

**Keywords:**

Head and Neck Squamous Cell Carcinoma, HNSCC, Melanoma

### More Information

**Description:** The goal of this study is to evaluate the combination of cabozantinib and nivolumab in people with advanced melanoma or squamous cell head and neck cancer. Researchers want to learn whether these drugs can help shrink or stabilize cancer and whether certain tumor biomarkers may help predict how well patients respond to treatment.

**Study Contact:** Kristen Nelson - [knelso65@fairview.org](mailto:knelso65@fairview.org)

**Principal Investigator:** Puneet Cheema

**Phase:** PHASE2

**IRB Number:** MMCROC100

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.